Literature DB >> 8845036

Local intravaginal vaccination of the female genital tract.

L Wassén1, K Schön, J Holmgren, M Jertborn, N Lycke.   

Abstract

In a clinical trial the authors tested whether local intravaginal or oral vaccination would stimulate a mucosal immune response in the female genital tract. The whole cell/B subunit (CTB) oral cholera vaccine was used. Two groups of previously unimmunized volunteers were given three doses of vaccine at 2-week intervals: a first group of seven women received oral immunizations and a second group of seven women were immunized locally in the genital tract by mixing the vaccine with a well defined gel, eldexomer, and applying it directly in the fornix of the vagina. The women were given the first vaccination on day 10 of the menstrual cycle. Sampling of peripheral blood and of cervical mucus (CM) using an Aspiglaire syringe was performed immediately prior to the first dose and at 8-10 days following the last immunization. The study showed that while only three of the seven orally immunized women responded with detectable IgA and IgG anti-CTB antibodies in the genital tract, six out of the seven women in the locally vaccinated group responded with genital tract antibodies. The responses were also generally stronger and CM contained higher specific IgA and secretory component containing anti-CTB titres in the locally vaccinated group. Of the orally vaccinated individuals all responded with increases in serum anti-CTB IgG and 4,7 also exhibited specific IgA serum titres. By contrast, only 3/7 in the intravaginal group responded with increases in serum IgG and IgA anti-CTB titers following immunization. The authors conclude that local intravaginal vaccination using a well-defined gel appears to be the route of choice to stimulate immunity in the female genital tract.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8845036     DOI: 10.1046/j.1365-3083.1996.d01-320.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  26 in total

1.  Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans.

Authors:  E L Johansson; L Wassén; J Holmgren; M Jertborn; A Rudin
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

2.  Generation of female genital tract antibody responses by local or central (common) mucosal immunization.

Authors:  H Y Wu; S Abdu; D Stinson; M W Russell
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

3.  Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans.

Authors:  A Rudin; E L Johansson; C Bergquist; J Holmgren
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

4.  Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination.

Authors:  K Eriksson; M Quiding-Järbrink; J Osek; A Möller; S Björk; J Holmgren; C Czerkinsky
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

5.  Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine.

Authors:  Jennifer R Carmichael; Sukumar Pal; Delia Tifrea; Luis M de la Maza
Journal:  Vaccine       Date:  2011-05-24       Impact factor: 3.641

6.  Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates.

Authors:  E L Johansson; C Rask; M Fredriksson; K Eriksson; C Czerkinsky; J Holmgren
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

7.  Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women.

Authors:  P A Kozlowski; S Cu-Uvin; M R Neutra; T P Flanigan
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

8.  Route of infection that induces a high intensity of gamma interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice.

Authors:  J U Igietseme; I M Uriri; S N Kumar; G A Ananaba; O O Ojior; I A Momodu; D H Candal; C M Black
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  Kinetics of local and systemic immune responses after vaginal immunization with recombinant cholera toxin B subunit in humans.

Authors:  Lotta Wassen; Marianne Jertborn
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

Review 10.  The vagina as a route for drug delivery: a review.

Authors:  Sushma Srikrishna; Linda Cardozo
Journal:  Int Urogynecol J       Date:  2012-12-11       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.